Malvern’s Ocugen Licenses OCU400 Gene Therapy to Celairis Therapeutics for Australia, New Zealand, and Southeast Asia

Published · 5 min read · Greater Philadelphia
Malvern’s Ocugen Licenses OCU400 Gene Therapy to Celairis Therapeutics for Australia, New Zealand, and Southeast Asia

 Ocugen, a Malvern, Pennsylvania-based biotechnology company developing gene therapies for blindness diseases, has granted Celairis Therapeutics exclusive rights to commercialize its investigational retinitis pigmentosa (RP) treatment in Australia, New Zealand, and the member states of the Association of Southeast Asian Nations (ASEAN), the companies announced on November 10, 2026. It is Ocugen’s third regional licensing deal for OCU400, its modifier gene therapy.

“Australia, New Zealand, and ASEAN are large, diverse and complex markets, and establishing a partnership with a regional company like Celairis and its strong local network is critical to our goal of global patient access,” said Dr. Shankar Musunuri, Chairman, Chief Executive Officer, and Co-Founder of Ocugen.

Inside the Deal

Ocugen will receive an upfront license fee and potential development and milestone payments totaling up to $7.1 million. Of that, $6.1 million is tied to the upfront payment and OCU400’s topline results, expected in the first quarter of 2027. Ocugen will also receive a high single-digit percentage royalty on net sales and 50% of gross profits from OCU400 sales in the region.

The companies expect to sign a supply agreement under which Ocugen will manufacture OCU400. Celairis will handle regulatory submissions, market access, and commercialization across the region, which Ocugen says has an estimated 725 million people.

“This agreement marks our third strategic regional partnership for OCU400, underscoring the growing momentum behind our global access strategy and bringing our potential one-time treatment gene therapy closer to patients around the world,” Musunuri said.

What’s Next for OCU400

RP is a group of inherited retinal diseases that cause progressive vision loss and, in many cases, blindness. OCU400 is investigational and has not been approved or registered in any of the markets covered by the agreement.

Ocugen is running the Phase 3 liMeliGhT trial of OCU400, with topline data expected in the first quarter of 2027. The company then plans to file a Biologics License Application (BLA) in the U.S. and a Marketing Authorization Application (MAA) in Europe, followed by submissions in the Celairis territory.

For Celairis, the partnership fits its model of bringing late-stage therapies to the region:

“Ocugen is the kind of partner Celairis was built for: a late-stage program, a clear strategy for reaching patients globally, and a conviction we share that geography should not decide access to new medicines,” said Matt Zeller, Chief Executive Officer, Co-Founder, and Managing Director of Celairis. “Celairis brings the development, regulatory, and market access capability to do that across our region, and we look forward to building the relationship with Ocugen.”

About Ocugen

Ocugen’s modifier gene therapy platform takes a gene-agnostic approach. Rather than targeting a single gene mutation, its therapies are designed to address underlying disease biology by restoring balance across multiple gene networks. Beyond RP, the company is developing programs for Stargardt disease and geographic atrophy, an advanced form of dry age-related macular degeneration.

About Celairis Therapeutics

Founded in 2026 and headquartered in Sydney, Australia, Celairis licenses, develops, and commercializes therapies across 14 markets in Australia, New Zealand, Taiwan, and ASEAN. It focuses on oncology and hematology, specialty conditions, and rare diseases, and runs clinical development, regulatory approval, market access, supply chain, and commercial launch on a single platform.

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding the anticipated benefits to Ocugen of the license agreement and planned supply agreement with Celairis, as well as statements regarding strategy, the potential amounts of milestone payments and profit share payments that may be received under the license agreement, including Ocugen’s obligations under its prior license and commercialization agreements, the timing of regulatory submissions and the potential availability of OCU400 in the Territory, business plans and objectives for Ocugen’s clinical programs, plans and timelines for the preclinical and clinical development of Ocugen’s product candidates, including the therapeutic potential, clinical benefits and safety thereof, expectations regarding timing, success and data announcements of current ongoing preclinical and clinical trials, including the timing of data readouts and marketing applications, the ability to initiate new clinical programs, statements regarding qualitative assessments of available data, potential benefits, expectations for ongoing clinical trials, anticipated regulatory filings and anticipated development timelines, statements regarding potential market size and commercial possibilities of Ocugen’s product candidates, which are subject to risks and uncertainties. Ocugen may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from Ocugen’s current expectations, including, but not limited to, the risks that the license agreement and planned supply agreement with Celairis will not lead to the current anticipated benefits to Ocugen; that the supply agreement with Celairis will not be entered into; that OCU400 may not receive regulatory approval in any jurisdiction, including in the Territory; that preliminary, interim and top-line clinical trial results may not be indicative of, and may differ from, final clinical data; that unfavorable new clinical trial data may emerge in ongoing clinical trials or through further analyses of existing clinical trial data; that earlier non-clinical and clinical data and testing may not be predictive of the results or success of later clinical trials; and that clinical trial data are subject to differing interpretations and assessments, including by regulatory authorities. These and other risks and uncertainties are more fully described in Ocugen’s filings with the Securities and Exchange Commission (SEC), including the risk factors described in the section entitled “Risk Factors” in the quarterly and annual reports that Ocugen files with the SEC. Any forward-looking statements that Ocugen makes in this press release speak only as of the date of this press release. Except as required by law, Ocugen assumes no obligation to update forward-looking statements contained in this press release whether as a result of new information, future events, or otherwise, after the date of this press release.

Contacts

Ocugen Investors: Candice Masse, astr partners, [email protected] Media: Chris Clark, Ocugen, [email protected]

Celairis Therapeutics Media: [email protected]

Source: Ocugen, https://www.globenewswire.com/news-release/2026/11/10/3399307/0/en/ocugen-and-celairis-therapeutics-enter-into-exclusive-license-agreement-for-ocu400-in-australia-new-zealand-and-asean.html on November 10, 2026. Republished with credit to the original author. Read the original article.